Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Status:
Completed
Trial end date:
2019-03-14
Target enrollment:
Participant gender:
Summary
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F)
fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance
imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or
stage II-IV prostate cancer.